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SLITRK2 variants associated with
neurodevelopmental disorders impair excitatory
synaptic function and cognition in mice
Salima El Chehadeh 1,2,3,33, Kyung Ah Han4,33, Dongwook Kim4,33, Gyubin Jang4,33, Somayeh Bakhtiari5,6,
Dongseok Lim4, Hee Young Kim4, Jinhu Kim4, Hyeonho Kim4, Julia Wynn7, Wendy K. Chung7,8,
Giuseppina Vitiello9, Ioana Cutcutache10, Matthew Page10, Jozef Gecz 11,12,13, Kelly Harper11,12, Ah-reum Han14,
Ho Min Kim 14,15, Marja Wessels16, Allan Bayat 17,18, Alberto Fernández Jaén 19, Angelo Selicorni20,
Silvia Maitz21, Arjan P. M. de Brouwer22, Anneke Vulto-van Silfhout22,23, Martin Armstrong24,
Joseph Symonds 25, Sébastien Küry 26,27, Bertrand Isidor26,27, Benjamin Cogné 26,27, Mathilde Nizon26,27,
Claire Feger28, Jean Muller 3,28, Erin Torti 29, Dorothy K. Grange30, Marjolaine Willems31,
Michael C. Kruer 5,6, Jaewon Ko 4 ✉, Amélie Piton 2,28,32 ✉ & Ji Won Um 4 ✉

SLITRK2 is a single-pass transmembrane protein expressed at postsynaptic neurons that
regulates neurite outgrowth and excitatory synapse maintenance. In the present study, we
report on rare variants (one nonsense and six missense variants) in SLITRK2 on the X
chromosome identiﬁed by exome sequencing in individuals with neurodevelopmental disorders. Functional studies showed that some variants displayed impaired membrane transport and impaired excitatory synapse-promoting effects. Strikingly, these variations abolished
the ability of SLITRK2 wild-type to reduce the levels of the receptor tyrosine kinase TrkB in
neurons. Moreover, Slitrk2 conditional knockout mice exhibited impaired long-term memory
and abnormal gait, recapitulating a subset of clinical features of patients with SLITRK2
variants. Furthermore, impaired excitatory synapse maintenance induced by hippocampal
CA1-speciﬁc cKO of Slitrk2 caused abnormalities in spatial reference memory. Collectively,
these data suggest that SLITRK2 is involved in X-linked neurodevelopmental disorders that
are caused by perturbation of diverse facets of SLITRK2 function.

A full list of author afﬁliations appears at the end of the paper.
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ntellectual disability (ID) affects about 3% of the general
population and is the most common reason for referral to
genetic centers. It is estimated that at least half of cases have a
monogenic cause, with more than 1000 genes corresponding to
an equivalent number of rare diseases currently identiﬁed. The
most frequently identiﬁed genes are responsible for at most 0.5%
of cases. All modes of transmission—autosomal dominant,
recessive, and X-linked (dominant or recessive)—are observed.
Because of the disproportionate number of males among individuals with ID and the possibility of performing genetic studies of
X-linked patterns of inheritance in large families, special attention
has been paid to identifying the genetic basis of X-linked ID
(XLID). Prior to the advent of next-generation sequencing (NGS),
major efforts by the EuroMRX consortium, the Sanger Center,
and other international groups encompassing thousands of
families1–4, led to the identiﬁcation of a large number of XLID
genes. The generalization of NGS approaches, including exome
sequencing and whole-genome sequencing has greatly accelerated
the discovery of autosomal and XLID genes and increased the
diagnostic yield of ID, resulting in a shortened diagnostic odyssey
for families and expanded access to genetic counseling, including
prenatal and pre-implantation genetic diagnosis. Thus, there are
now about ~130 identiﬁed XLID genes, with an additional ~50
potential candidate XLID genes5–7. These include SLITRK2, a
gene encoding a transmembrane protein that is highly expressed
in the brain.
Slit- and Trk-like family proteins, composed of six members
(Slitrk1-6), are type I transmembrane proteins that are strongly
expressed in the central nervous system8,9. Intriguingly, Slitrks
positively regulate excitatory and inhibitory synapse development
in cultured hippocampal neurons in a paralog-dependent
manner10,11. Extensive analyses have shown that Slitrks interact
with distinct members of the LAR-RPTP (leukocyte common
antigen-related receptor protein tyrosine phosphatase) family to
promote presynaptic assembly10,12. In addition, Slitrk5 interacts
with receptor tyrosine kinase TrkB in cis to regulate their interactions with LAR-RPTPs13. Structural analyses have further
demonstrated that the N-terminal leucine-rich repeat 1 (LRR1) of
Slitrks interacts with splicing variants of LAR-RPTPs that contain
an insert at the MeB site14,15. Divergent intracellular mechanisms
of Slitrk2 and Slitrk3 also appear to be involved in their synaptic
functions16,17. Furthermore, systematic analyses to investigate the
effects of previously reported SLITRK missense variants revealed
that a subset of SLITRK variants associated with neuropsychiatric
disorders18 disrupt the trafﬁcking of Slitrks to the cell surface and
impair their synapse-promoting function19. Collectively, these prior
studies have established Slitrks as important synapse organizers.
The precise role of the Slitrk2 protein has not yet been clearly
deﬁned. The human SLITRK2 gene is located on the X chromosome, and two missense variants, p. S549F and p.V89M, were
reported to be associated with schizophrenia in two female
patients who inherited the missense variants from their asymptomatic heterozygous mothers18. Furthermore, SLITRK2 interacts
with the PDZ domain-containing excitatory scaffold Shank317, a
gene associated with autism spectrum disorders (ASDs)20, suggesting its potential involvement in the pathogenesis of neurodevelopmental disorders (NDD).
Here, we report that eight individuals from seven unrelated
families with moderate to severe ID and/or NDDs, including
neuropsychiatric and behavioral problems, harbor rare potential
disease-causing variants of the X-linked gene, SLITRK2. We
systemically investigated the effects of SLITRK2 variants on biochemical properties, surface transport, ligand-binding activity,
and synaptogenic activities in cultured neurons. In addition, we
analyzed the synaptic and behavioral effects of a Slitrk2 deﬁciency
using Slitrk2 conditional knockout (cKO) mice.
2

Results
Identiﬁcation of individuals with rare variants in SLITRK2.
Exome sequencing, used as a diagnostic approach in individual
P1, identiﬁed a nonsense c.1381G>T p.E461* variant in the
SLITRK2 gene (Table 1 and Fig. S1a). Sanger sequencing conﬁrmed that this variant was present in his affected brother (P2),
but absent from mother’s blood, suggesting a de novo occurrence
in the maternal germ line (Fig. 1 and Fig. S1a). Because the
SLITRK2 gene contains only one coding exon, we suspected that
the mutant transcript does not undergo nonsense mRNAmediated decay. Through an international data-sharing arrangement initiated through Genematcher21, we identiﬁed six additional individuals with NDDs carrying rare nonsynonymous
SLITRK2 variants predicted to be damaging. Among those were
six missense variants—c.221T>C p.L74S (P7), c.628G>A p.E210K
(P10), c.934A>G p.T312A (P3), c.1121C>G p.P374R (P8),
c.1276C>T p.R426C (P4) and c.1531G>A p.V511M (P5), all
found in male individuals (except p.R426C)—that were not previously reported in hemizygous state in gnomAD (Table S1). In
all but one of these individuals, no other diagnostic candidate
variants were identiﬁed during exome sequencing analyses. In P7,
a likely pathogenic variant in the homeobox transcription factor
ARX (c.1109C>T p.A370V) was identiﬁed but this did not seem
likely to fully explain the patient’s phenotype, suggesting that the
p.L74S variant identiﬁed in SLITRK2 contributes to the observed
symptoms. One variant (p.R426C) occurred de novo, and
extended segregation analyses showed that one maternally
inherited variant (p.P374R) occurred de novo in the unaffected
mother. The remaining variants were maternally inherited. All of
these missense variants were predicted to be damaging, based on
analyses using SIFT and Polyphen2 (PPH2), with CADD scores
between 24.1 and 28.2 (Table S1). The amino acid residues
affected by the missense variants are all highly conserved across
species and are located in the extracellular part of the SLITRK2
protein (Fig. 1 and Fig. S2).
Seven additional missense SLITRK2 variants were identiﬁed in
seven unrelated male patients with NDDs. Among them: (i) a rare
missense variant (p.E555D) was identiﬁed in a male (P14) who also
carried a pathogenic variant in CUL4B, encoding a ubiquitin E3
ligase subunit. This CUL4B variant appeared sufﬁcient to explain
the majority of his clinical manifestations and the SLITRK2
p.E555D variant was therefore not considered as potentially
disease-causing; (ii) four other missense variants—c.601G>A
p.V201I (P13), c.931C>G p.P311A (P11), c.1451G>A p.R484Q
(P12), and c.2374C>T p.R792C (P9)—were also reported in the
hemizygous state in gnomAD (Table S1 and Fig. S1b). They were
not therefore likely to be disease-causing, particularly p. V201I
variant, which was detected in 19 hemizygous males from
gnomAD; and (iii) two additional missense variants were reported
in the Decipher database (https://www.deciphergenomics.org/)—
c.26G>T, p.S9I and c.44G>A, p.G15E—in individuals with nervous
system abnormalities.
Clinical manifestations in individuals with rare variants in
SLITRK2. We collected clinical information for the eight individuals with likely pathogenic variants, P1-5, P7-8, and P10
(Table 1 and Supplementary information). The mean age at
examination was 16.9 years (range: 8–30 years). All but one
patient had mild to severe intellectual disability and speech delay
(mostly severe). Neurological regression was observed in one
patient after the age of 6. Patients mainly presented with neuropsychiatric and behavioral issues, including major anxiety (7/8),
ASD (4/8), and aggressiveness (2/8). Two patients had attentiondeﬁcit hyperactivity disorder (ADHD) with executive impairment, and two were diagnosed with hyperactivity or agitation.
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Table 1 Clinical manifestations identiﬁed in individuals harboring potential disease-causing SLITKR2 variants.
P1

P2

P3

P4

P7

P8

P5

P10

SLITRK2 variant

p.E461*

p.E461*

p.T312A

p.R426C

p.P374R

p.V511M

p.E210K

Sex, age
OFC (SDS)
Height (SDS)

M, 30 yrs
>+2 SDS
0 SDS

M, 28 yrs
>+2 SDS
0 SDS

M, 21 yrs
N.A.
<−5 SDS

F, 13 yrs
<−2 SDS
−2.5 SDS

p.L74S
(+ARX
variant)
M 12 yrs
+1.5 SDS
+1 SDS

M, 11 yrs
NA
+0.5 SDS

M, 8 yrs
+0.8 SDS
+0.5 SDS

Feeding difﬁculties
Kyphoscoliosis
Developmental delay

−
−
+

−
−
+

+GOR
+
+

−
+
+

−
−
+

Speech

Delay

Delay

+ GT
+
Normal before
regression
Regression

M, 12 yrs
N.A.
Short stature <
−2 DS
+ GOR, PEG
+
+

Absent

Delay

Delay

Delay

ID

Mild

Severe

Severe

−

+ (10 yrs)

+ (11 mths)

Moderate
to severe
−

Mild

Seizure (age
at onset)
Seizures type

Moderate
to severe
−

Moderate
to severe
−

−

−

−

Generalized
seizures

−

Focal
seizures

−

−

Spasticity/Dystonia

−

−

Multifocal,
prominent in
left
central region
Spasticity

−

−

−
Anxiety

−
Major anxiety,
ASD, mutism,
aggressiveness

+a
−

+
ASD, anxiety,
hyperactivity

−
Anxiety,
ADHD,
very
sensitive,
easily
frustrated

Dystonic
diplegia
+g
Anxiety, ADHD

−

Unsteady gait
Neuropsychiatric
manifestations

Diplegic
cerebral palsy
+c
ASD, anxiety,
mutism,
aggressiveness

Normal

Normal

+b

+d

Not done

+f

+e

Not done

Other
Brain MRI anomalies

+ (8 yrs)

+GOR
−
+
Language
impairment
Border line

−
ASD, severe
anxiety,
ADHD,
OCD,
vocal tics

a: Conﬁned to a wheelchair at 21 yrs; b: severe cerebral and cerebellar volume loss, ventricle dilation, atrophy of corpus callosum and brainstem, bilateral hippocampal atrophy with increased FLAIR signal;
c: walking with support; d: thin corpus callosum, white matter diffuse reduction, and leukomalacia; e: paucity of white matter, bilateral periventricular lesions, lateral ventricles dilation; f: unspeciﬁc minor
white substance punctate changes on the right side around the trigonum; g: uses a walker and wheelchair for getting around.
ADHD attention-deﬁcit hyperactivity disorder, ASD autism spectrum disorder, GOR gastroesophageal reﬂux, GT gastric tube feeding, mths months, MRI magnetic resonance imaging, OCD obsessivecompulsive disorder, OFC occipitofrontal circumference, PEG percutaneous endoscopic gastrostomy, SDS standard deviation score, yrs years.

One patient had obsessive-compulsive behavior, vocal tics,
“meltdowns” and tantrums. We also noted an unsteady gait (4/6),
spasticity and/or dystonia (3/8), and seizures (3/8). Several
patients (4/8) had kyphoscoliosis. Three patients had short stature
(≤2 SDS). The patients for whom we were able to get photographs
were not clearly dysmorphic except for one patient (Supplementary information). Occipitofrontal circumference measurements were highly variable, including two patients with
macrocephaly and one patient with microcephaly. Brain magnetic
resonance imaging (MRI) of most patients was normal or
revealed nonspeciﬁc anomalies (4/8), including white matter
reduction, ventricular dilation, and thin corpus callosum; three
patients had white matter anomalies (Table 1).
Biochemical, structural, and ligand-binding phenotypes of
disease-associated SLITRK2 variants. To investigate the structural effect of patient variants on human SLITRK2, we predicted
the structure of SLITRK2 using AlphaFold222,23. Three variants
(L74S, V201I, and E210K) are located in the LRR1 domain (aa
C33-D270) and six variants (P374R, R426C, E461*, R484Q,
V511M, and E555D) are located in the LRR2 domain (Fig. 2, top).
Free energy calculations indicated that three variants (L74S,
P374R, and V511M) are predicted to affect the structural stability
of the protein (Table S2), possibly causing misfolding and aberrant trafﬁcking. In particular, a point mutation in the nonpolar
leucine, L74, to a polar serine residue in the consensus

LxxLxLxxNxL motif of LRR1-1 is expected to disrupt hydrophobic interactions with neighboring nonpolar residues (V54,
L69, L77, L91, and L93). Similarly, mutation of P374 to arginine is
expected to disrupt the LRRNT hydrophobic core of LRR2,
comprising with V357 and L380. A point mutation, resulting in
the replacement of a small, nonpolar valine by a long methionine
(V511M), may collapse LRRCT folding of the LRR2 domain. The
crystal structure of the human SLITRK1 LRR1 domain in complex with PTPδ Ig1-3 has shown that E206 on the concave surface
of SLITRK1 makes ionic interactions with the side chain of K135
and main chain of V13614. Mutation of SLITRK2 E210 corresponding to SLITRK1 E206 to positively charged lysine would be
expected cause charge repulsion, thus interrupting the interaction
of SLITRK2 LRR1 with LAR-RPTPs. Because cysteine residues
are usually undesirable in exposed regions of a protein unless they
acquire functions such as metal binding24, the R426C variant on
the concave surface may adversely affect protein stability. However, other variants exposed on the surface (E461*, R484Q, and
E555D in LRR2) and V201I, which form hydrophobic networks
in LRR1, are predicted to have little effect on the threedimensional (3D) structure of SLITRK2.
To further investigate the impact of amino acid substitutions
on the structure and/or synaptic function of SLITRK2, we
generated mammalian expression vectors encoding SLITRK2
variants identiﬁed in individuals with NDD, both those
considered potentially disease-causing and those identiﬁed in
gnomAD (Table S1 and Fig. 3a). As controls, in addition to the
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Fig. 1 Identiﬁcation of SLITRK2 variants in individuals with NDD. a Pedigree of families with rare SLITRK2 variants. b Representation of the SLITRK2
protein, including the different variants identiﬁed in individuals with NDD and not previously reported in the hemizygous state in the gnomAD database
(Purple, variants occurring de novo in the proband or his mother; blue, variants inherited from unaffected mothers without additional information; green,
variants identiﬁed in gnomAD in at least two hemizygous males).

V201I variant, we included two other variants—c.967A>G
p.S323N and c.1765G>A p.V589I—present in 6 and 139 males
from gnomAD respectively and therefore presumed to be benign
(Table S1). Notably, P374 and V511 residues in human SLITRK2
are conserved in other human SLITRK proteins at equivalent
positions, but none of the other residues exhibit complete
sequence identity across the six SLITRK members (Fig. S2a). The
two variants from Decipher, S9I and G15E, are located in the
signal peptide of SLITRK2, which is expected to be cleaved after
membrane targeting. Thus, for these two variants, we generated
pCMV5-SLITRK2 vector harboring its own signal peptide,
whereas the other variants were generated using the pDisplaySLITRK2 vector (Fig. 3a). Most of these residues are quite
evolutionarily conserved among various vertebrate species,
implying their possible functional signiﬁcance (Fig. S2b).
We then examined the expression levels and intracellular
transport properties of the various SLITRK2 variants following
expression in human embryonic kidney 293 T (HEK293T) cells
(Fig. 3). Immunoblot analyses of lysates of HEK293T cells
transfected with vectors encoding HA-tagged full-length
SLITRK2 wild-type (WT) or the respective variants showed that
total protein expression levels of all SLITRK2 point mutants
(except E461*) were comparable to those of SLITRK2 WT
(Fig. 3b). The E461* variant, which resulted in a premature
termination codon, yielded a truncated protein of ~60 kDa in
SDS-PAGE analyses (Fig. 3b). Notably, unlike SLITRK2 WT,
which is expressed as both N-glycosylated and non-glycosylated
protein species, three SLITRK2 variants (L74S, P374R, and
R426C) in HEK293T cells were detected as immature, nonglycosylated forms (Fig. S3). We next examined the surface and
4

intracellular protein levels of SLITRK2 WT and the indicated
SLITRK2 variants in HEK293T cells (Fig. 3c, d). In keeping with
the glycosylation proﬁles (Fig. S3), only three SLITRK2 variants
(L74S, P374R, and R426C) displayed signiﬁcantly reduced surface
levels, reﬂecting their complete entrapment in an intracellular
compartment (Fig. 3c, d), in the absence of altered cellular
membrane integrity (as monitored by transferrin receptor
expression; Fig. S4). The E461* variant also exhibited reduced
surface levels (Fig. 3c, d), in agreement with the absence of a
transmembrane region in this variant; thus, this truncated
SLITRK2 is likely secreted (Fig. S5). Results obtained using
surface biotinylation assays were consistent with these ﬁndings,
showing markedly lower surface expression levels of L74S, P374R,
R426C, and E461* variants (Fig. S6). Note that, although S9I and
G15E variants are located in the SLITRK2 signal peptide, they did
not affect the membrane transport of SLITRK2 (Fig. 3c, d).
To determine whether the various SLITRK2 variants affected the
interactions with PTPδ, an extracellular ligand of SLITRK2, we
assayed cell-surface binding of recombinant Ig-fusion proteins of
PTPδ (IgC-PTPδ) or IgC alone (negative control) with
HEK293T cells expressing HA-tagged SLITRK2 variants (Fig. S7).
IgC-PTPδ proteins avidly bound to HEK293T cells expressing
SLITRK2 variants, except those expressing a subset of SLITRK2
variants with defective surface transport properties (Fig. S7). IgC
did not bind to any tested SLITRK2 variants (Fig. S7).
To ensure that the subset of the SLITRK2 variants with impaired
surface transport properties exhibited similar trafﬁcking defects in
neurons, we transfected cultured hippocampal neurons with WT or
variant SLITRK2 and analyzed them by immunocytochemistry.
Whereas most HA-tagged SLITRK2 variants were transported into
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Fig. 2 Structural model of human SLITRK2 and patient variants. Model structure of human SLITRK2 LRR1 and LRR2 domains presented as a cartoon. Top:
LRR1 domain, C33-D270 (left); LRR2 domain, P341-P579 (right). LRR N-terminus, LRR motifs, and LRR C-terminus are depicted in yellow, gray, and orange,
respectively. Black dotted lines represent ﬂexible linkers between LRR1 and LRR2 domains. Bottom: Close-up views of mutated and neighboring residues in
LRR1 and LRR2 domains. Residues corresponding to patients’ variants described in the current study are presented as red sticks and labeled. The structure
of human PTPδ Ig2 (teal) from the crystal structure of the human SLITRK1/human PTPδ Ig1-3 (PDB ID:4RCA) complex was used as a reference for
potential interactions between human SLITRK2 and PTPδ Ig2. For clarity, the human SLITRK2 model is rotated 90° around the x-axis in the close-up views
of E210K, E461*, R484Q, and V511M.

dendrites as efﬁciently as SLITRK2 WT (Fig. 4), three SLITRK2
variants (L74S, P374R, and R426C) were either completely retained
in the cell body of transfected neurons, or displayed markedly
impaired trafﬁcking into dendrites (Fig. 4), as judged relative to
immunoﬂuorescence signals in the somatic compartment of
transfected neurons. Puzzlingly, HA immunoreactive intensity in
the somatic compartment was not decreased in neurons transfected
with L74S, P374R, or R426C (see Fig. 4b), possibly reﬂecting
imprecise evaluation owing to saturation of HA immunoreactivity
in transfected neurons. We thus repeated the same experiments
using a subset of SLITRK2 variants and quantiﬁed HA immunoreactive intensity in transfected neurons imaged using settings that
prevented saturation of immunoﬂuorescence signals (Fig. S8a, b).
We found that HA immunoreactivity was signiﬁcantly increased in
somatic compartments of neurons expressing L74S or P374R, but
not in those of neurons expressing R426C (Fig. S8a, b). Similar
ﬁndings were also obtained using Slitrk2-deﬁcient cultured neurons
(Fig. S9). These ﬁndings are also consistent with the slight increase
in R426C entrapment in an intracellular compartment (i.e., cisgolgi) of cultured neurons, as assessed by its colocalization with
anti-GM130 (Fig. S10). No alterations in dendritic branching were
observed in neurons expressing SLITRK2 WT or the indicated
SLITRK2 variants (Fig. S8c). The E461* variant also exhibited

impaired dendritic trafﬁcking and reduced levels of HA immunoﬂuorescence signals in the somatic compartment (Fig. 4), in
agreement with the absence of a transmembrane region; in E461*,
again suggesting that the truncated SLITRK2 protein is likely
secreted. These observations suggest that the surface transport
deﬁciency observed in heterologous cells is similarly recapitulated in
cultured hippocampal neurons. Taken together, these data suggest
that one subset of SLITRK2 variants observed in patients with
neurodevelopmental disorders causes improper biochemical processing and abnormal trafﬁcking.
Synaptic phenotypes of disease-associated SLITRK2 missense
variants. SLITRK2 was previously shown to trigger presynaptic
differentiation when expressed in heterologous cells and cocultured
in contact with axons10,12,19. To test whether the surface transportdefective SLITRK2 variants exhibit differences in presynaptic
differentiation-inducing ability, we performed heterologous synapseformation assays using HEK293T cells expressing SLITRK2 WT or
the indicated SLITRK2 variants (Fig. S11). SLITRK2 WT robustly
recruited clustering of both the glutamatergic presynaptic marker
VGLUT1 (vesicular glutamate transporter 1) and GABAergic presynaptic marker GAD67 (glutamic acid decarboxylase 67 kDa)
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around SLITRK2-expressing HEK293T cells, whereas L74S, P374R,
R426C, and E461* were functionally inactive in recruiting both
VGLUT1 and GAD67, as expected given their impaired surface
expression levels and PTP-binding activities (Fig. S11; see Figs. 3c, d,
S6 and S7).
6

Generation of Slitrk2-cKO mice. To evaluate the cellular effects
of SLITRK2 variants, we generated conditional Slitrk2-KO
(Slitrk2-cKO) mice. Transgenic mice with a deletion of Slitrk2
were generated by crossing homozygous Slitrk2-ﬂoxed mice, in
which exon 2 and exon 3 are ﬂanked by loxP sites, with a Cre
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Fig. 3 Impaired surface trafﬁcking of a subset of SLITRK2 variants. a Schematic diagrams depicting the SLITRK2 variants analyzed in the current study.
b Representative immunoblots from HEK293T cells transfected with the indicated WT or mutant forms of SLITRK2. Samples containing equal amounts of
protein were resolved by SDS-PAGE and immunoblotted using anti-HA or GFP antibodies; β-actin was used as a loading control. Molecular mass markers
are labeled in kilodaltons. The experiments were independently repeated three times. c Surface expression analysis of HEK293T cells expressing the
indicated WT or mutant forms of SLITRK2. Transfected cells were immunostained with mouse anti-HA antibodies (cyan) and detected with FITCconjugated anti-mouse secondary antibodies under non-permeabilized conditions, followed by permeabilization of cells. Cells were then stained ﬁrst with
rabbit anti-HA antibodies (magenta) and then with Cy3-conjugated anti-rabbit secondary antibodies. Scale bar, 10 μm (applies to all images).
d Quantiﬁcation of the proportion of cells exhibiting surface expression. All data are shown as means ± SEMs (‘n’ denotes the number of images from three
independent experiments; WT, n = 10; L74S, n = 7; E210K, n = 9; P311A, n = 7; T312A, n = 6; P374R, n = 7; R426C, n = 8; E461*, n = 8; R484Q, n = 6;
V511M, n = 6; E555D, n = 6; R792C, n = 7; S323N, n = 13; V589I, n = 13; V201I, n = 16; WT, n = 7; S9I, n = 7; and G15E, n = 7; **p < 0.01, ***p < 0.001;
ANOVA with a non-parametric Kruskal–Wallis test). See Source data for raw data values and Supplementary Table 4 for statistical details.

recombinase driver line under control of the Nestin promoter
(Nestin-Cre) (Fig. 5a, b). Quantitative RT-PCR analyses showed
that mRNA levels of Slitrk2, but not those of the other Slitrks,
were completely eliminated in Nestin-Slitrk2 mice (Fig. 5c).
Nestin-Slitrk2 male mice weighted marginally (but signiﬁcantly)
less at postnatal day 30 (P30), P40, and P50 compared with
control mice, a generalized metabolic phenotype of the NestinCre driver line25 (Fig. 5d), although their brain weights and size
were comparable (Fig. 5e, f). Gross morphology, cortical thickness
and neuron numbers, including interneuron numbers, were
comparable between Nestin-Slitrk2 mice and control littermates,
as assessed by Nissl staining (Fig. 5g) and immunostaining for the
neuron-speciﬁc marker NeuN (Fig. 5h, i) and GABAergic interneuron marker GAD67 (Fig. 5j, k). In addition, semi-quantitative
immunoblot analyses conﬁrmed complete elimination of detectable Slitrk2 protein in Nestin-Slitrk2 mice (Fig. 5l, m), as assessed
with the Slitrk2-speciﬁc polyclonal antibody, JK177 (Fig. S12),
and further showed that expression levels of various synaptic
proteins in the cortex of Nestin-Slitrk2 mice were comparable to
those of littermate control mice (Fig. 5l, m). Moreover, ventricle
volumes in Nestin-Slitrk2 mice were comparable to those of
control mice (Fig. S13).
Slitrk2-cKO induces an impairment in excitatory synaptic
development that is not reversed by reintroduction of a subset
of SLITRK2 patient variants. Slitrk2 was previously shown to
speciﬁcally promote excitatory, but not inhibitory, synapse
maintenance in cultured neurons and hippocampal CA1
neurons10,17,19. To address this, we ﬁrst examined whether Slitrk2
deletion induced a speciﬁc decrease in excitatory synapse numbers and synaptic transmission in cultured hippocampal neurons.
Immunostaining neurons at DIV14 with antibodies to VGLUT1
and SHANK, markers for excitatory postsynaptic density,
revealed a reduction in the density of excitatory synaptic puncta
immunoreactive to both VGLUT1 and SHANK (Fig. S14a, b). As
expected, neither the density nor size of inhibitory synaptic
puncta was changed in neurons immunostained with antibodies
to VGAT and GABAAγ2, an inhibitory postsynaptic marker (Fig.
S14a, b, d).
To assess whether the potential disease-causing SLITRK2
variants affect the excitatory synapse-promoting function of
SLITRK2 WT, we infected cultured hippocampal Slitrk2-cKO
neurons with lentiviruses expressing either inactive Cre (ΔCre;
Control) or active Cre recombinase at DIV5 and co-transfected
them with human SLITRK2 expression variants and EGFP at
DIV8–9. We subsequently immunostained these infected/cotransfected neurons with antibodies to synaptophysin, SHANK
and EGFP (to visualize the transfected neurons) at DIV13–14. The
density, but not the size, of excitatory synaptic puncta immunoreactive to both synaptophysin and SHANK was signiﬁcantly
reduced in Slitrk2-deﬁcient neurons (Fig. 6a, b; Fig. S14e). Coexpression of SLITRK2 WT completely reversed the excitatory

synaptic deﬁcits observed in Slitrk2-deﬁcient neurons (Fig. 6a, b).
In contrast, co-expression of the SLITRK2 variants, L74S, P374R,
R426C, or E461*, consistently failed to rescue the deﬁcits in
excitatory synapses (Fig. 6a, b), in agreement with the results
obtained in heterologous synapse-formation assays (Fig. S11).
Strikingly, expression of T312A also failed to rescue the deﬁcits in
excitatory synapses (Fig. 6a, b), despite the fact that this SLITRK2
variant exhibited expression levels, surface transport, and presynaptic differentiation-inducing abilities comparable to those of
Slitrk2 WT (see Figs. 3, 4, S4, S6, and S11).
To corroborate these immunocytochemical results, we measured miniature excitatory postsynaptic currents (mEPSCs) in
cultured hippocampal neurons using whole-cell electrophysiological recordings (Fig. 6c–e). We found that the frequency, but not
amplitude, decay time or rise slope, of mEPSCs was markedly
decreased in Slitrk2-deﬁcient cultured neurons (Fig. 6c–g; see also
Fig. S15). In contrast, Slitrk2 deletion did not affect the frequency
or amplitude of miniature inhibitory postsynaptic currents
(mIPSCs) in cultured hippocampal neurons (Fig. S15). Coexpression of SLITRK2 WT or the indicated SLITRK2 variants
completely reversed decrease in mEPSC frequency (Fig. 6c, e),
whereas co-expression of SLITRK2 variants defective in rescuing
anatomical deﬁcits failed to rescue mEPSC frequency (Fig. 6c, e).
Consistent with results obtained in cultured hippocampal
neurons, immunohistochemical analyses using Nestin-Slitrk2
mice revealed that the density of VGLUT1 and PSD-95 puncta
was signiﬁcantly decreased in a subset of hippocampal CA1 layers
(stratum oriens [SO] and stratum radiatum [SR]) (Figs. S16).
These results collectively suggest that the synaptic phenotypes of
the various SLITRK2 variants likely reﬂect perturbation of diverse
facets of SLITRK2 functions.
Reduced TrkB levels induced by SLITRK2 WT, but not by
disease-associated SLITRK2 variants. Previous studies have
shown that SLITRK5 acts as a co-receptor for TrkB that
orchestrates brain-derived neurotrophic factor (BDNF)-TrkBdependent trafﬁcking and signaling13, and that an obsessivecompulsive disorder (OCD)-associated SLITRK5 missense variant
impairs SLITRK5 binding to TrkB26. Thus, we next analyzed
whether the identiﬁed SLITRK2 variants also altered TrkB binding, assessed by coimmunoprecipitation assays in HEK293T cells.
We found that disease-linked SLITRK2 variants with impaired
excitatory synapse maintenance did not affect the ability of
SLITRK2 to bind TrkB (Fig. S17a, b).
BDNF plays critical roles in neuronal survival and synaptic
plasticity through activation of a full-length receptor (TrkB-FL)
while truncated TrkB isoforms (TrkB-T) are presumed to
competitively inhibit BDNF-mediated TrkB signaling in certain
contexts27. Excitotoxic stimulation of cultured neurons with
glutamate downregulated TrkB-FL, resulting in downregulation
of BDNF-TrkB signaling28. In addition, calpain activation triggers
the truncation of TrkB-FL, leading to downregulation of BDNF-
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TrkB signaling29. These ﬁndings suggest that disease-linked
SLITRK2 variants could alter BDNF-TrkB signaling. To test this
possibility, we infected DIV3 cortical cultured neurons with
lentiviruses expressing SLITRK2 WT or the indicated variants,
and collected the infected neuronal lysates at DIV14. Immunoblot
analyses revealed that overexpression of SLITRK2 WT
8

signiﬁcantly decreased TrkB-FL levels, but markedly increased
TrkB-T levels (Fig. 7a, b), suggesting that SLITRK2 might reduce
forward trafﬁcking of TrkB and/or trigger the truncation of TrkBFL. Strikingly, T312A abolished the ability of SLITRK2 WT to
decrease TrkB-FL levels (Fig. 7a, b). In addition, the effects of
L74S, P374R, R426C, or E461* were similar to those of T312A
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Fig. 4 Impaired dendritic targeting of a subset of SLITRK2 variants in cultured hippocampal neurons. a Representative images of hippocampal neurons
transfected with the indicated WT or mutant forms of SLITRK2 at DIV10. The transfected neurons at DIV14 were double-immunostained for antibodies
against the somatodendritic marker, MAP2 (cyan), and HA (magenta). Scale bar, 20 μm (applies to all images). b, c Somatic (b) or dendritic (c) targeting
of WT or the indicated mutant forms of SLITRK2 in hippocampal neurons was quantiﬁed by measuring average intensity of HA immunoﬂuorescence in
primary dendrites. The average intensities of SLITRK2 WT and variants in the soma region of transfected neurons were also quantiﬁed. All data are shown
as means ± SEMs (‘n’ denotes the number of neurons from three independent experiments; WT, n = 12; L74S, n = 10; E210K, n = 10; P311A, n = 10; T312A,
n = 10; P374R, n = 11; R426C, n = 10; E461*, n = 11; R484Q, n = 10; V511M, n = 10; E555D, n = 11; R792C, n = 10; S323N, n = 10; V589I, n = 10; V201I,
n = 10; **p < 0.01, ***p < 0.001, ****p < 0.0001; ANOVA with a non-parametric Kruskal–Wallis test). See Source data for raw data values and
Supplementary Table 4 for statistical details.

Fig. 5 Generation of Slitrk2-cKO mice. a Strategy used to generate Slitrk2-cKO mice. LoxP sites were introduced at positions ﬂanking the neomycin gene,
FLP recombinant target (FRT), and exon 2–3 (E2 and E3) of the Slitrk2 gene. Black arrows indicate forward and reverse primers used for genotyping. Note
that lacZ and neomycin cassettes are two separate markers. b PCR genotyping of Slitrk2-ﬂoxed mice (top) and Nestin-Cre;Slitrk2-cKO (Nestin-Slitrk2) mice
(bottom). The band size for the Slitrk2-ﬂoxed allele was 245 bp. The 400-bp Cre-speciﬁc PCR product was detected only in Nestin-Slitrk2 mice.
c Quantitative RT-PCR analyses of Slitrk mRNA levels in Nestin-Slitrk2 mice. Data are mean ± SEMs (n = 4 mice; *p < 0.05; two-tailed Mann–Whitney U
test). d Body weights of Nestin-Slitrk2 and Slitrk2-ﬂoxed (Ctrl) mice at P30, P40, and P50. Data are means ± SEMs (‘n’ denotes the number of mice; P30:
Ctrl, n = 15; Nestin-Slitrk2, n = 10; P40: Ctrl, n = 20; Nestin-Slitrk2, n = 14; P50: Ctrl, n = 20; Nestin-Slitrk2, n = 14; *p < 0.05, ****p < 0.0001; two-tailed
Mann–Whitney U test). e, f Representative photographs of whole brains (e) and quantiﬁcation of brain weights and size (f) of P42 Nestin-Slitrk2 and
Slitrk2-ﬂoxed (Ctrl) mice. Data are means ± SEMs (‘n’ denotes the number of mice; Ctrl and Nestin-Slitrk2, n = 5; two-tailed Mann–Whitney U test).
g Normal gross morphology of the Nestin-Slitrk2 brain at 7 wks, as revealed by Nissl staining. Scale bar: 1 mm (applies to both top and bottom).
h Representative images of NeuN (a neuronal marker) staining in the Nestin-Slitrk2 brain. Normal numbers of neurons in hippocampal regions. Top,
hippocampus; bottom, CA1 stratum pyramidale layer. Scale bar: 1 mm (top) and 20 µm (bottom). i Summary graphs for neuron density and cortical
thickness. Data are means ± SEMs (‘n’ denotes the number of mice; neuron density: Ctrl and Nestin-Slitrk2, n = 4; cortical thickness: Ctrl and Nestin-Slitrk2,
n = 6; two-tailed Mann–Whitney U test). j Representative images of GAD67 (GABAergic interneuron marker) staining in the hippocampal CA1 of NestinSlitrk2 mice. Scale bar: 0.1 mm. k Summary data for GAD67 staining from (j). Data are means ± SEMs (n = 3 mice each after averaging data from
3 sections/mouse; two-tailed Mann–Whitney U test). l, m Representative immunoblots (l) of hippocampal lysates, and summary data showing synaptic
protein levels (m) in crude synaptosomal fractions of P42 control and Nestin-Slitrk2 brains, analyzed by semi-quantitative immunoblotting. Data are
means ± SEMs (n = 4 mice/group; *p < 0.05, ***p < 0.001; two-tailed unpaired t-test). See Source data for raw data values and Supplementary Table 4 for
statistical details.

(Fig. 7a, b). To corroborate these observations, we examined
whether a SLITRK2 deletion affects the levels of TrkB-FL and TrkBT in hippocampal CA1 lysates (Fig. 7c, d). We found that a deletion
of SLITRK2 induced a signiﬁcant increase in TrkB-FL and decrease
in TrkB-T (Fig. 7c, d), conﬁrming the SLITRK2 gain-of-function
effects. These results underscore the contribution of a normal

BDNF-TrkB activation range to the regulation of SLITRK2mediated excitatory synaptic functions.
The accumulation of misfolded proteins is well known to trigger
cellular stress responses, such as the endoplasmic reticulum (ER)
stress response and unfolded protein response30–32. Thus, we
hypothesized that expression of a subset of SLITRK2 variants (i.e.,
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Fig. 6 Impaired rescue of excitatory synapse development and transmission in Slitrk2-cKO hippocampal neurons by a subset of SLITRK2 variants.
a Triple-immunoﬂuorescence analysis of EGFP (blue), the presynaptic marker synaptophysin (SynPhys; magenta), and the excitatory postsynaptic marker
SHANK (yellow) in mature cultured neurons (DIV14) derived from Slitrk2f/f mice infected with lentiviruses expressing ΔCre or Cre at DIV5. For rescue
experiments, neurons infected with lentiviruses expressing Cre at DIV5 were transfected with vectors expressing WT or the indicated mutant forms of
SLITRK2 together with EGFP vector at DIV8–9. Scale bar: 10 µm (applies to all images). b Quantiﬁcation of images in (a), showing the density of SynPhys
+SHANK+ puncta. All data are shown as means ± SEMs (‘n’ denotes the number of cells from ﬁve independent experiments; Control vs. experimental
group: ΔCre, n = 22; Cre, n = 25; +WT, n = 18; +L74S, n = 12; +E210K, n = 17; +P311A, n = 16; +T312A, n = 18; +P374R, n = 16; +R426C, n = 13; +E461*,
n = 15; +R484Q, n = 16; +V511M, n = 15; +E555D, n = 14; +R792C, n = 21; +S323N, n = 14; +V589I, n = 17; *p < 0.05, **p < 0.01, ***p < 0.001; Cre vs.
experimental group: #p < 0.05, ##p < 0.01; ANOVA with a non-parametric Kruskal–Wallis test). c–g Representative mEPSC traces (c) and quantiﬁcation of
amplitudes (d), frequencies (e), decay time (f) and rise time (g) of mEPSCs recorded from hippocampal cultured neurons infected with lentiviruses
expressing ΔCre or Cre at DIV5 and transfected with vectors expressing WT or the indicated mutant forms of SLITRK2 together with EGFP vector. All data
are shown as means ± SEMs (‘n’ denotes the number of cells from six independent experiments; Control vs. experimental group: ΔCre, n = 48; Cre, n = 46;
+WT, n = 41; +L74S, n = 20; +E210K, n = 22; +P311A, n = 24; +T312A, n = 19; +P374R, n = 36; +R426C, n = 20; +E461*, n = 22; +R484Q, n = 29;
+V511M, n = 19; +E555D, n = 16; +R792C, n = 16; +S323N, n = 20; +V589I, n = 17; **p < 0.01, ***p < 0.001, ****p < 0.0001; experimental group; Cre vs.
experimental group; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001; ANOVA with a non-parametric Kruskal–Wallis test). See Source data for raw
data values and Supplementary Table 4 for statistical details.

L74S, T312A, P374R, and R426C) exhibiting entrapment in
intracellular compartments could induce an ER stress response in
cultured hippocampal neurons. However, immunoblot analyses
using lysates of neurons overexpressing SLITRK2 WT or the
indicated SLITRK2 variants showed no difference in the levels of
BiP, which are activated transcriptionally by ER stressors, between
SLITRK2 WT and mutant variants (Fig. S17c, d), suggesting no
effects of these variants on cellular stress responses.
Slitrk2-cKO mice exhibit memory deﬁcits and abnormal gait.
We then tested whether Slitrk2-cKO mice exhibited the behavioral
features that manifest in patients with NDD and SLITRK2 variants
(see Table 1). To this end, we performed a battery of behavioral
tests, including those measuring learning and memory, locomotion, anxiety, and motor coordination (Fig. 8 and Fig. S18). Tenweek-old male Nestin-Slitrk2 mice displayed comparable exploratory behavior (assessed by open-ﬁeld tests) (Fig. S18a, b),
10

sociability, and social novelty recognition memory (assessed by
three-chamber tests) as littermate control mice, showing preference for the ﬁrst novel mouse over an inanimate object (Fig.
S18c, d) and preference for a novel stranger mouse over familiar
mouse (Fig. S18e, f). However, Nestin-Slitrk2 mice exhibited
reduced anxiety-like behavior, as evidenced by increased time
spent in open arms (with a similar number of entries into each
open arm) in the elevated plus-maze test, without a change in time
spent in the light compartment in the light-dark test (Fig. S18g–i).
Moreover, Nestin-Slitrk2 mice showed impaired spatial learning
and memory (assessed by novel object-recognition tests), although
spontaneous alternation in Y-maze tests was similar to that of
littermate control mice (Fig. S18j–m). We further examined spatial
reference memory, as evaluated by the Barnes maze test33. Both
Control and Nestin-Slitrk2 mice learned to locate the target hole
during the course of the training period, as indicated by gradual
reductions in the number of search errors, escape latency and total
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Fig. 7 Alterations of full-length TrkB protein levels in cultured neurons by a subset of SLITRK2 variants. Cultured cortical neurons were infected with
lentiviruses expressing WT or the indicated mutant forms of SLITRK2. Levels of TrkB were examined by semi-quantitative immunoblotting using antibodies
against TrkB or phospho-TrkB. FL full-length, T truncated. b Quantiﬁcation of protein levels from (a). Summary data showing plots from ﬁve independent
experiments. Data are mean ± SEMs (*p < 0.05; ANOVA with a non-parametric Kruskal–Wallis test). c Hippocampal CA1 lysates from Slitrk2-ﬂoxed mice
infected with AAVs expressing ΔCre or Cre were examined by semi-quantitative immunoblotting using antibodies against TrkB or phospho-TrkB. FL
full-length, T truncated. d Quantiﬁcation of protein levels from (c). Data are means ± SEMs (n = 5 mouse samples; *p < 0.05; two-tailed unpaired t-test).
See Source data for raw data values and Supplementary Table 4 for statistical details.

distance traveled, indicating normal acquisition of spatial reference
memory in Nestin-Slitrk2 mice (Fig. 8a–d). We then conducted the
ﬁrst probe test 3 days after the last day of training and the second
probe test after 17 days. In the ﬁrst probe test, the number of
search errors was comparable between Control and Nestin-Slitrk2
mice (Fig. 8e). In contrast, the accuracy of spatial memory of
Nestin-Slitrk2 mice in the second probe tests was worse than that
of control mice, suggesting that retention of spatial reference
memory is impaired in Nestin-Slitrk2 mice (Fig. 8f).
Because some NDD patients reported in the current study suffer
from spasticity and/or dystonia and unsteady gait (Table 1), we
also examined whether Nestin-Slitrk2 mice exhibit deﬁcits in ﬁne
motor coordination. To this end, we analyzed the juvenile (P20)
and adult (P65) Nestin-Slitrk2 mice by measuring overlap distance,
stance width, step angle, and gait symmetry. At both ages, the
mean stride length, stance length, and sway length of forelimbs and
hindlimbs of Nestin-Slitrk2 mice were comparable to those of
control littermate mice (Fig. 8g–i). Strikingly, Nestin-Slitrk2 mice
exhibited increased front/hind paw overlap, despite normal limb
strength (assessed by grip strength test) (Figs. 8g–i, S18n). Taken
together, these extensive behavioral data suggest that Nestin-Slitrk2
mice exhibit impaired learning and memory and abnormal
footprint patterns, partly recapitulating the clinical phenotypes of
patients with SLITRK2 variants (see Table 1).
Correlation of impaired hippocampal CA1 excitatory synapse
properties of Slitrk2-cKO mice with deﬁcits in spatial reference
memory. Because Nestin-Slitrk2 mice exhibited impairment in
the Barnes maze test (Fig. 8a–f), a hippocampal CA1-dependent
spatial task34, we asked whether loss of Slitrk2 in the hippocampal
CA1 region could recapitulate this behavioral deﬁcit. To this end,
we stereotactically injected adeno-associated viruses (AAVs)
expressing Cre or ΔCre (Ctrl) into the CA1 of adult Slitrk2-ﬂoxed
mice and performed semi-quantitative immunohistochemistry
and electrophysiological recordings three weeks after injections
(Fig. 9a, b). We found that the frequency, but not amplitude, of
mEPSCs was markedly decreased in hippocampal CA1-speciﬁc
Slitrk2-cKO mice (Fig. 9c–e). Moreover, these mice exhibited a
signiﬁcant reduction in the integrated intensity of VGLUT1 and
PSD-95 puncta in the SO and SR layers (Fig. 9f, g), without

changes in VGAT puncta in any examined hippocampal CA1
layer (Fig. S19), in keeping with the anatomical phenotype of
Nestin-Slitrk2 mice (Fig. S16). Notably, co-expression of
SLITRK2 WT, but not that of the SLITRK2 T312A variant,
completely rescued the decreased integrated intensity of VGLUT1
and PSD-95 puncta in hippocampal CA1-speciﬁc Slitrk2-cKO
mice (Fig. 9f, g). These results reinforce the phenotype of
SLITRK2 T312A in hippocampal CA1 pyramidal neurons.
Finally, to determine whether CA1-speciﬁc elimination of
Slitrk2 expression leads to long-term spatial memory deﬁcits, we
performed Barnes maze tests using CA1-speciﬁc Slitrk2-cKO
mice. Similar to the behavioral phenotype of Nestin-Slitrk2 mice,
CA1 region-speciﬁc Slitrk2-cKO mice also exhibited impaired
retention of spatial reference memory (Fig. 9h–l). Collectively,
these results support the conclusion that SLITRK2 synaptic
functions in the hippocampal CA1 are essential for execution of
normal spatial tasks in mice.
Discussion
Although numerous genes encoding synaptic cell adhesion proteins (CAMs) have been identiﬁed as causative factors for a
variety of neurodevelopmental and/or neuropsychiatric disorders,
it had remained to be determined whether a subset of neurological symptoms of patients with these disorders are caused by
alterations in synaptic adhesion signaling pathways that are not
clearly established. As a member of a vertebrate-speciﬁc synaptic
cell adhesion protein family, SLITRK2 speciﬁcally functions in
mediating proper excitatory synapse development35. In particular, SLITRK2 is required for organizing trans-synaptic signaling
pathways involved in excitatory presynaptic assembly and postsynaptic maintenance by binding to PTPσ and PDZ domaincontaining scaffolds10,17,36. In addition, our previous study
demonstrated that a subset of disease-associated SLITRK2 missense variants induce impaired dendritic targeting of Slitrk2 in
neurons, leading to dysfunctions of excitatory synapse
maintenance19. The SLITRK2 V89M variant reduced excitatory
synapse density, likely through its deleterious effects on surface
expression and dendritic targeting19. Similarly, a series of other
SLITRK variants associated with Tourette’s syndrome, trichotillomania, schizophrenia, or OCD was shown to trigger loss of
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Fig. 8 Slitrk2-cKO mice display mild learning and memory deﬁcits and abnormal gait. a Schematic depiction (top) of Barnes maze test. b–d Number of
errors before ﬁrst encountering the escape hole (b) escape latency (c) and total distance (d) for Control and Nestin-Slitrk2 mice during the training session.
Data are presented as means ± SEMs (‘n’ denotes the number of mice; Control, n = 17; Nestin-Slitrk2, n = 12; two-way ANOVA with Sidak’s multiple
comparisons test). Representative track images (bottom) from ﬁrst and last days of the training. e, f Number of errors before ﬁrst encountering the escape
hole for control and Nestin-Slitrk2 mice during 1st (e) and 2nd probe (f) trials. Data are presented as means ± SEMs (‘n’ denotes the number of mice;
Control, n = 15; Nestin-Slitrk2, n = 12; *p < 0.05; two-tailed Mann–Whitney U test). Representative track images (bottom) from 1st and 2nd probe trials.
g Representative image of the footprint patterns of juvenile (P20) and adult (P65) control and Nestin-Slitrk2 mice. h, i Footprint patterns were analyzed
based on overlap, stride length, stance length, and sway length. P20 (h) and P65 (i) Nestin-Slitrk2 mice exhibited longer overlap length. Data are shown as
means ± SEMs (‘n’ denotes the number of mice; P20: Control, n = 10; Nestin-Slitrk2, n = 12; P65: Control, n = 14; Nestin-Slitrk2, n = 15; *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001; two-tailed Mann–Whitney U test). See Source data for raw data values and Supplementary Table 4 for statistical details.

the respective SLITRK protein functions in cultured hippocampal
neurons19,26. These results collectively suggest that pathogenic
SLITRK genetic variants likely induce loss-of-function of corresponding SLITRKs, accounting for the pathogenesis of patients
with neurological disorders. However, previous studies, which
primarily employed knockdown (KD) and/or overexpression
approaches, preclude ﬁrm conclusions about SLITRK2 functions.
Previous Slitrk2 loss-of-function studies performed in cultured
neurons and mice produced contradictory results10,17, with
Slitrk2 KD in cultured neurons reducing excitatory synapse
density, and Slitrk2 KD in hippocampal CA1 neurons failing to
affect excitatory synapse density10,17. These results were previously attributed to differences in genetic manipulations, cellular
preparation, or other unknown factor(s). Extensive analyses using
Slitrk2-cKO mouse-derived cultured neurons recapitulated our
previous anatomical results using Slitrk2 KD10, in addition to
exhibiting marked reduction in excitatory synaptic transmission.
Moreover, Slitrk2 deletion in adult mouse hippocampal CA1
neurons similarly reduces the frequency of mEPSCs, in contrast
to the absence of an effect of global Slitrk2 KD on mEPSCs17.
These results again underscore the importance of conﬁrmatory
analyses using a sophisticated system and approaches to elucidate
functions of synaptic proteins.
12

In the current study, we identiﬁed SLITRK2 variants in NDD
characterized by developmental delay and speech delay, mild to
severe ID, and various neurological and behavioral comorbidities.
Seven of the eight individuals with potential disease-causing variants had signiﬁcant anxiety, and four patients were diagnosed
with autism spectrum disorder. Other behavioral diagnoses
include ADHD with executive difﬁculties, hyperactivity, or agitation. Several individuals had unsteady gait associated with spasticity and/or dystonia and three patients had seizures, of variable
type, with the severity of ID ranging from mild to severe. Such
clinical heterogeneity among individuals is often reported in
NDDs associated with mutations in the same gene and even
precisely the same mutation37,38, suggesting that other genetic
and/or environmental modifying factors might also be involved.
SLITRK2 variants have previously been reported in two females
with schizophrenia18, but no patients affected by ID and/or NDD
phenotypes and carrying SLITRK2 pathogenic variants have been
reported to date. Of the seven potential disease-causing variants
identiﬁed in this study, ﬁve induced prominent alterations in the
properties of SLITRK2. Among these, three variants (L74S, P374R,
and R426C) perturbed surface transport of SLITRK2, accompanied by impaired binding to LAR-RPTPs and synaptogenic
activity, similar to most of known SLITRK1/4/5 substitutions that
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Fig. 9 Proper Slitrk2 function in the hippocampal CA1 is required for mediating spatial reference memory in mice. a Experimental conﬁguration for
electrophysiology and immunohistochemistry experiments (c–g). b Representative brain sections illustrating the precise targeting of AAVs for expression
of Cre recombinase in the hippocampal CA1. Scale bar: 500 µm. c–e Representative traces (c) and summary graphs showing the frequency (d) and
amplitude (e) of mEPSCs recorded from Slitrk2-ﬂoxed mice injected with AAVs expressing ΔCre or Cre. Data are shown as means ± SEMs (ΔCre, n = 13;
Cre, n = 20; *p < 0.05; two-tailed Mann–Whitney U test). f, g Representative images (f) and summary graphs quantifying the integrated intensity (g) of
VGLUT1 and PSD-95 puncta. Data are shown as means ± SEMs (ΔCre, n = 6; Cre, n = 6; Cre+WT, n = 5; and Cre+T312A, n = 5 mice; *p < 0.05,
**p < 0.01, ****p < 0.0001; ANOVA with Tukey’s test). Scale bar, 10 µm (applies to all images). h Experimental conﬁguration for Barnes Maze tests (i–l).
i Representative traces of locomotive behavior for Barnes Maze tests. Target box is indicated with a yellow circle. j Number of errors before ﬁrst
encountering the escape hole, escape latency, and total distance for Slitrk2-ﬂoxed mice injected with ΔCre (Control) or Cre during the training session.
Data are presented as means ± SEMs (ΔCre, n = 12; Cre, n = 8; two-way ANOVA with Sidak’s multiple comparisons test). k, l Number of errors before ﬁrst
encountering the escape hole for Slitrk2-ﬂoxed mice injected with ΔCre (Control) or Cre during 1st (k) and 2nd (l) probe trials. Data are presented as
means ± SEMs (ΔCre, n = 12; Cre, n = 8; *p < 0.05, **p < 0.01; two-tailed unpaired t-test). See Source data for raw data values and Supplementary Table 4
for statistical details.

represent loss-of-function mutations. One variant (E461*) in
SLITRK2 was a nonsense variant, and resulted therefore in a
truncated SLITRK2 protein. The ﬁfth variant, T312A, induced
normal surface expression, and normal extracellular ligandbinding and synaptogenic activity, albeit with markedly reduced
excitatory synapse number and excitatory synaptic transmission.
Remarkably, these ﬁve SLITRK2 variants abrogated the ability of

SLITRK2 WT to negatively regulate TrkB-FL levels in neurons,
revealing the signiﬁcance of interactions between SLITRK2 and
TrkB in terms of preventing SLITRK2 dysfunction-induced
pathogenic effects. Given the well-established centrality of TrkBmediated signaling in excitatory synapse development39, it is
plausible that selection of speciﬁc binding partners (i.e., LARRPTPs vs. TrkB) through ﬁne regulation of SLITRK2-mediated
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extracellular interactions constitutes an important signaling
pathway for excitatory synapse organization. Our preliminary
analyses suggested that Slitrk2, Slitrk3, and Slitrk5, but not other
Slitrks, bind to TrkB (Fig. S20). Further experiments are warranted
to dissect the molecular determinants underlying Slitrk2/5-TrkB
interactions.
Our extensive behavioral analyses showed that Slitrk2 loss-offunctions in mice recapitulated a subset of behavioral symptoms
found in patients with SLITRK2 variants. Strikingly, the current
study demonstrated that selective elimination of Slitrk2 expression in the hippocampal CA1 results in impaired retention of
spatial reference memory. It is likely that speciﬁc alterations in
synaptic inputs on CA1 neurons, possibly from either entorhinal
cortex afferents or CA3 Schaffer-collateral afferents, are responsible for abnormalities in this behavioral task. Whether SLITRK2
is involved in the assembly of speciﬁc hippocampal circuits
remains to be determined. In addition, Nestin-Slitrk2 mice
exhibited impaired long-term memory and altered footprint
patterns. However, these mice displayed normal grip strength and
somewhat enhanced motor coordination and learning. In general,
the cerebellum is critical for coordinating movements, and its
dysfunction often leads to uncoordinated walking or gait
disturbance40, a feature of patients harboring a subset of SLITRK2
variants, even though they were not clearly ataxic and the brain
MRI did not show cerebellar anomalies (except for one patient
with severe cerebral and cerebellar volume loss). Although the
current study primarily correlated SLITRK2 synaptic functions in
the hippocampal CA1 with spatial memory performance, future
studies are warranted to identify the neuronal populations and/or
neural circuits embedded in other brain areas that might
underpin abnormal footprint patterns seen in Nestin-Slitrk2 mice.
Moreover, most patients harboring potential disease-causing
variants in SLITRK2 are anxious, whereas Nestin-Slitrk2 mice
appeared to exhibit reduced anxiety-like behavior in the elevated
plus-maze tests. Future studies utilizing knock-in mice expressing
disease-associated SLITRK2 variants should help resolve this
issue using additional behavioral paradigms that examine
anxiety-like behavior. Most patients exhibit seizures and speech
delay. Thus, it will be necessary to clarify whether Nestin-Slitrk2
mice exhibit seizure-like phenotypes or communication deﬁcits
by measuring electroencephalography and measuring ultrasonic
vocalization, respectively. Because our various analyses did not
reveal any prominent phenotypes in the case of E210K and
V511M (predicted to be deleterious by in silico programs), their
pathogenicity remains uncertain, although it is still possible that
these variants are involved in SLITRK2-associated pathophysiology via as-yet unidentiﬁed mechanism(s) encompassing early
brain developmental processes. Given that Slitrk2 is also
expressed in speciﬁc astrocytic subtypes in adult mice41, it is
reasonable to speculate that these SLITRK2 missense variants
with no clear phenotypes in current functional assays might
affect speciﬁc aspects of astrocytic functions that remain to be
determined.
In conclusion, we demonstrated nonsense and missense variants in SLITRK2 in a novel form of X-linked NDD characterized
by different degrees of ID associated with motor, speech, and
behavioral impairments, that are caused by perturbation of
SLITRK2 function. Further studies with larger cohorts are needed
to conﬁrm the involvement of this gene in a NDD and better
delineate the clinical manifestations of the latter, especially at the
behavioral level.
Methods
Participants and genetic analysis. Individuals were referred by clinical geneticists
for genetic testing as part of routine clinical care. All patients enrolled and/or their
legal representative signed informed consent for research use and authorization for
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publication. All the institutions received local institutional review board (IRB)
approval to use these data in research. The main IRB approval was obtained from
the Ethics Committee of the Strasbourg University Hospital (CCPPRB). Individuals
P1 and P2 (male siblings) were followed up in the Department of Clinical Genetics
of Montpellier University Hospital, and exome sequencing was performed for P1 in
the Molecular Genetics Laboratory of Strasbourg University Hospital, France. The
six remaining patients (P3–P10) were recruited through an international collaborative study and data-sharing through Genematcher21. All patients were followed by a referring clinical geneticist and underwent exome sequencing in the
different molecular laboratories as detailed in Supplementary information. Sanger
sequencing conﬁrmed the SLITRK2 variants in all affected probands and was used
for segregation studies. Variants have been submitted to ClinVar database. The
referring physicians completed clinical forms and sent morphological pictures and
brain MRI reports, when available. Clinical information is detailed in Table 1. All
patients’ families provided written informed consent, and all procedures performed
in the studies were done in accordance with the ethical standards of the local
institutional research committee and the Declaration of Helsinki. Effects of
SLITRK2 missense variants were predicted using PolyPhen-242, SIFT43, and CADD
(combined annotation-dependent depletion) scores44.
Expression vectors. pDisplay-SLITRK2 missense variants (L74S, V201I, E210K,
P311A, T312A, S323N, P374R, R426C, R484Q, V511M, E555D, V589I, and R792C)
were generated by polymerase chain reaction (PCR)-based mutagenesis with PrimeSTAR HS DNA polymerase (Takara) using a pDisplay SLITRK2 wild-type (WT)
construct as a template. pDisplay-SLITRK2 E461* was generated by PCR ampliﬁcation of the indicated region of human SLITRK2 (amino acid [aa] 22–460), followed by
digestion with XmaI and SacII and subcloning into a pDisplay vector (Invitrogen).
pCMV5-SLITRK2 missense variants (S9I and G15E) were generated by PCR-based
mutagenesis with PrimeSTAR HS DNA polymerase (Takara) using a pCMV5-WT
SLITRK2-mVenus construct as a template. pCMV6-XL4-SLITRK2 variant-Fc constructs (L74S, P374R, and R426C) were generated by PCR-based mutagenesis with
PrimeSTAR HS DNA polymerase (Takara) using the pCMV6-XL4-SLITRK2-Fc
construct as a template. pCMV6-XL4-SLITRK2 E461*-Fc was generated by PCR
ampliﬁcation of the indicated region of human SLITRK2 (aa 22–460) using the
pCMV6-XL4-SLITRK2-Fc construct as a template, followed by digestion with NotI
and XbaI and subcloning into a modiﬁed pCMV6-XL4 vector in frame as a C-terminal
Fc fusion protein. L-313 SLITRK2 missense variants were constructed by amplifying
the indicated full-length SLITRK2 variants by PCR, digesting with NheI and BsrGI,
and subcloning the resulting products into the L-313 vector (lentiviral expression
vector). pAAV-SLITRK2 T2A-GFP variants (WT and T312A) were generated by PCR
ampliﬁcation of the indicated region of human SLITRK2, followed by digestion with
XbaI and BamHI and subcloning into the pAAV-T2A-GFP vector. pDisplay-SLITRK3
and pDisplay-SLITRK5 were generated by PCR ampliﬁcation of mouse Slitrk3 (aa
28–652) and human SLITRK5 (aa 41–664), respectively, followed by digestion with
XmaI and SacII and subcloning into the pDisplay vector. pCAGG-His-HA-Nlgn2 was
generated by PCR ampliﬁcation of rat Nlgn2 (aa 1-678) using pCMV5-Nlgn2 as a
template, followed by digestion with EcoRI and NotI and subcloning into the pCAGGHis-HA vector. pCMV-SPORT6-TrkB was purchased from Korea Human Gene Bank.
The following constructs were previously described: pDisplay-SLITRK2 WT19,
pCMV5-SLITRK2-mVenus10, pDisplay-SLITRK110, pDisplay-SLITRK410, pCMV-IgC
PTPδ19, and pAAV-T2A-GFP45. FSW‐ΔCre and FSW‐Cre were gifts from Dr. Pascal
S. Kaeser (Harvard University, Cambridge, MA, USA). pCMV6-XL4-SLITRK2-Fc was
a gift from Dr. Davide Comoletti (Victoria University, New Zealand)46.
Antibodies. A polyclonal rabbit antibody against SLITRK2 was generated using a
fusion protein of glutathione S-transferase (GST) with human SLITRK2 (aa
705–784) produced in BL21 Escherichia coli and puriﬁed on a glutathioneSepharose column (GE Healthcare). Following immunization of rabbits with GSTSLITRK2 [705-784], the SLITRK2-speciﬁc antibody, designated JK177 (RRID:
AB_2892626), was afﬁnity-puriﬁed using a GST-SLITRK2 [705-784]-immobilized
Sulfolink column (Pierce). The following commercially available antibodies were
used: mouse monoclonal anti-GM130 (clone 35/GM130; BD Transduction
Laboratories; Cat# 610822; RRID: AB_398141), rabbit monoclonal anti-TfR (clone
EPR20584; Abcam; Cat# ab214039; RRID: AB_2904534), guinea pig polyclonal
anti-VGLUT1 (Millipore; Cat# AB5905; RRID: AB_2301751), mouse monoclonal
anti-GAD67 (clone 1G10.2; Millipore; Cat# MAB5406; RRID: AB_2278725),
mouse monoclonal anti-Synaptophysin (clone SVP-38; Sigma-Aldrich; Cat# S5768;
RRID: AB_477523), mouse monoclonal anti-PSD-95 (clone K28/43; NeuroMab;
Cat# 75-028; RRID: AB_2877189), rabbit polyclonal anti-GABAAγ2 (Synaptic
Systems; Cat# 224 003; RRID: AB_2263066), guinea pig polyclonal anti-VGAT
(Synaptic Systems; Cat# 131 004; RRID: AB_887873), mouse monoclonal anti-HA
(clone 16B12; BioLegend; Cat# 901501; RRID: AB_2565006), mouse monoclonal
anti-MAP2 (clone AP-20; Sigma-Aldrich; Cat# M1406; AB_477171), rabbit polyclonal anti-MAP2 (Abcam; Cat# ab32454; AB_776174),rabbit monoclonal antiTrkB (clone 80E3; Cell Signaling; Cat# 4603; RRID: AB_2155125), rabbit monoclonal anti-phospho-TrkB (Thermo Fisher; Cat# PA5-36695; RRID: AB_2553666),
rabbit monoclonal anti-BiP (clone C50B12; Cell Signaling; Cat# 3177; RRID:
AB_2119845), goat polyclonal anti-GFP (Rockland; Cat# 600-101-215; RRID:
AB_218182), mouse monoclonal anti-GluN1 (clone 54.1; Millipore; Cat# MAB363;
RRID: AB_94946), rabbit polyclonal anti-NR2A (Millipore; Cat# 07-632; RRID:
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AB_310837), mouse monoclonal anti-β-actin (clone C4; Santa Cruz; Cat# sc47778; RRID: AB_2714189), mouse monoclonal anti-NeuN (clone A60; Millipore;
Cat# MAB377; RRID: AB_2298772), HRP-goat anti-human IgG crossed-adsorbed
secondary antibody (Thermo Fisher; Cat# 62-8420; RRID: AB_2533962), Cy3AfﬁniPure donkey Anti-rabbit IgG antibodies (Jackson ImmunoResearch; Cat#
711-165-152; RRID: AB_2307443), Cy3-AfﬁniPure donkey anti-mouse IgG antibodies (Jackson ImmunoResearch; Cat# 715-165-150; RRID: AB_2340813), Cy3donkey anti-human IgG antibodies (Jackson ImmunoResearch; Cat# 709-165-149;
RRID: AB_2340535), Cy3-donkey anti-guinea pig IgG antibodies (Jackson
ImmunoResearch; Cat# 706-035-148; RRID: AB_ 2340447), FITC-AfﬁniPure
donkey anti-mouse IgG antibodies (Jackson ImmunoResearch; Cat# 715-095-150;
RRID: AB_2340792), FITC-AfﬁniPure donkey anti-goat IgG antibodies (Jackson
ImmunoResearch; Cat# 705-095-147; RRID: AB_2340401), FITC-AfﬁniPure
Donkey anti-rabbit IgG antibodies (Jackson ImmunoResearch; Cat# 711-095-152;
RRID: AB_2315776), and goat anti-guinea pig IgG antibodies (Thermo Fisher;
Cat# A-21450; RRID: AB_141882). The rabbit polyclonal anti-VGLUT1 (JK111;
RRID: AB_2810945) and the rabbit polyclonal anti-PSD-95 (JK016; RRID:
AB_2722693) were previously described17. Rabbit polyclonal anti-pan-Shank
(1172; RRID: AB_2810261), rabbit polyclonal anti-GluA1 (1193; RRID:
AB_2722772), and rabbit polyclonal anti-GluA2 (1195; RRID: AB_2722773) were
gifts from Dr. Eunjoon Kim (KAIST, Korea) and previously described51. See
Supplementary Table 3 for detailed information of antibody dilutions.
Cell culture. HEK293T cells (ATCC; CRL-3216) were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM; Welgene) supplemented with 10% fetal bovine
serum (FBS; Tissue Culture Biologicals) and 1% penicillin-streptomycin (Thermo
Fisher) at 37 °C in a humidiﬁed 5% CO2 atmosphere. All procedures were performed according to the guidelines and protocols for rodent experimentation
approved by the Institutional Animal Care and Use Committee of Daegu
Gyeongbuk Institute of Science and Technology (DGIST).
Cell-surface binding assays. Recombinant PTPδ Fc-fusion proteins were produced in HEK293T cells. HEK293T cells were transfected with a PTPδ-IgC construct or pCMV-IgC empty vector. After 72 h, the media from transfected cells
were collected, and 50 mM HEPES (pH 7.4) and 0.5 mM EDTA were added.
Soluble Fc-fusion proteins were puriﬁed using protein A-Sepharose beads (GE
Healthcare). Pulled-down proteins were eluted with 0.1 M glycine (pH 2.2) and
then neutralized with 1 M Tris-HCl (pH 8.0). HEK293T cells expressing HASLITRK2 and its variants were incubated with 10 µg/ml of the indicated PTPδ Fcfusion proteins. Images were acquired using a confocal microscope (LSM800;
Zeiss).
Biotinylation assays. HEK293T cells were transfected with HA-tagged SLITRK2
WT or the indicated missense variants. After 48 h, cells were washed twice with icecold phosphate-buffered saline (PBS), incubated with 1 mg/ml SulfoNHS-LCbiotin (Pierce) in ice-cold PBS for 30 min on ice, rinsed brieﬂy once with 0.1 M
glycine in PBS, and incubated with 0.1 M glycine/PBS for 10 min at room temperature to completely quench biotin reactions. Cells were lysed with lysis buffer
(1% Triton X-100, 0.1% SDS, 50 mM Tris pH 7.4, 150 mM NaCl, and protease
inhibitors) and incubated for 20 min on ice. After removal of cell debris by centrifugation, 250 µg of lysates was incubated with 30 µl streptavidin agarose beads
(Pierce) for 4 h at 4 °C. After washing beads three times with lysis buffer, surfacelabeled proteins were eluted with 2X sample buffer and analyzed by immunoblotting using the indicated antibodies. Anti-transferrin receptor (TfR) and β-actin
antibodies were used as surface and total protein loading controls, respectively.
Staining for surface/intracellular protein levels. HEK293T cells were transfected with expression vectors for HA-SLITRK2 WT or the indicated variants.
After 48 h, cells were washed twice with PBS, ﬁxed with 3.7% formaldehyde for
10 min at 4 °C, and blocked with 3% horse serum/0.1% bovine serum albumin
(BSA; crystalline grade) in PBS for 15 min at room temperature. Surface-expressed
SLITRK2 protein was then detected by staining with mouse anti-HA antibody at
room temperature. After 90 min, cells were washed twice with PBS and incubated
with FITC-conjugated anti-mouse antibodies for 1 h at room temperature. Cells
were then permeabilized with PBS containing 0.2% Triton X-100 for 10 min at 4 °C
and incubated with rabbit anti-HA antibody for 90 min at room temperature to
label intracellularly expressed SLITRK2 proteins, followed by incubation with Cy3conjugated anti-rabbit secondary antibodies.
Production of recombinant viruses
Lentiviruses. Lentiviruses were produced by transfecting HEK293T cells with three
plasmids—lentivirus vectors, psPAX2, and pMD2.G—at a 2:2:1 ratio. After 72 h,
lentiviruses were harvested by collecting the media from transfected HEK293T cells
and centrifuging at 1000 × g to remove cellular debris, as previously described47.
Adeno-associated viruses (AAVs). For high-efﬁciency transfections, AAVs were
packaged with pHelper and AAV1.0 (serotype 2/9) capsids, as previously
described48. Brieﬂy, HEK293T cells were co-transfected with pHelper and
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pAAV10.2/9 vectors together with pAAV-hSynI-SLITRK2-T2A-EGFP, pAAVhSynI-SLITRK2-T2A-EGFP (T312A), pAAV-hSynI-ΔCre-EGFP, or pAAV-hSynICre-EGFP. Cells were harvested 72 h later, lysed, mixed with 40% polyethylene
glycol and 2.5 M NaCl, and centrifuged at 2000 × g for 30 min. The resulting pellets
were resuspended in HEPES buffer (20 mM HEPES, 115 mM NaCl, 1.2 mM CaCl2,
1.2 mM MgCl2, 2.4 mM KH2PO4), mixed with an equal volume of chloroform, and
centrifuged at 400 × g for 5 min. The supernatants were concentrated three times
with a Centriprep centrifugal ﬁlter (15 ml, 4310; Millipore) at 1220 × g for 5 min
each and then with an Amicon Ultra centrifugal ﬁlter (0.5 ml, 3 K MWCO; Millipore) at 16,000 × g for 10 min. The infectious titer of viruses was assessed by qRTPCR detection of EGFP sequences with subsequent reference to a standard curve
generated using the pAAV-U6-EGFP plasmid.
Animals. All mice were on a C57BL/6J background, produced by back-crossing
with C57BL/6J wild-type (WT) mice (purchased from Jackson Research Laboratory). The mice were kept and produced in the animal facility of Daegu Gyeongbuk
Institute of Science and Technology under standard, temperature-controlled
laboratory settings, including a 12-h light/dark cycle (lights on at 7 am) and free
access to water and food. Pregnant Sprague-Dawley rats (Daehan Biolink) were
used to prepare in vitro cultures of dissociated hippocampal neurons. All procedures were carried out in compliance with the guidelines and protocols for rodent
experimentation in accordance with protocols (DGIST-IACUC-19052109-00)
approved by the Institutional Animal Care and Use Committee of Daegu
Gyeongbuk Institute of Science and Technology.
Generation of Slitrk2-ﬂoxed mice. The C57BL/6J mouse strain was used to
produce our Slitrk2-cKO mice. All mice were housed in a speciﬁc pathogen-free
facility.
Targeting strategy. The knockout strategy for conditional deletion of Slitrk2 targeted exon 2–3 using the Cre-loxP system. Speciﬁcally, 5′ loxP was inserted into
intron 1, and Frt-Neo-Frt-3′ loxP was inserted downstream of exon 3; mouse
embryonic stem cell (mESC)/homologous recombination (HR) technology developed by Biocytogen was used to establish the Slitrk2-cKO mouse model.
Donor vector construction. The 5′ and 3′ homologous arms used in gene-targeting
span ~3.5 kB and 3.0 kB, respectively. The targeting vector also expresses the
diphtheria toxin A (DTA) gene as a negative screening tag, which can be used to
deplete ESC clones with non-homologous recombination and improve ESC clone
screening efﬁciency.
Microinjection. The targeting vector was linearized and electroporated into C57BL/
6J mESCs. After G418 selection, a total of 1000 clones were selected in three
separate rounds. Selected cell clones were veriﬁed by Southern blotting, karyotyping, and sequence validation of PCR products. Chimeric mice were generated
by injecting positively selected C57BL/6J mESCs into a total of 80 (two rounds of
30 and 50) pre-implantation BALB/c mouse embryos (blastocysts).
Southern blot analysis. Chimeric offspring were crossed with WT C57BL/6 mice to
produce the F1 generation. Germline transmission was then conﬁrmed by Southern
blotting and PCR analysis of tail DNA from F1 generation mice. The restriction
enzymes EcoRI (5′ Probe-A), HindIII (Neo Probe (3′)), and SacI (3′Probe-A) (all
from New England Biolabs) were used for Southern blot analysis of genomic DNA.
After digestion, genomic DNA extracted from mouse tails was separated on a 1%
agarose gels and transferred to a positively charged nylon membrane (Hybond N+;
Amersham International plc). The membrane was hybridized using DIG Easy Hyb
Granules (Roche Applied Science Inc.) at 42 °C overnight in a mixture containing a
PCR-generated probe labeled using the PCR DIG probe synthesis kit (Roche
Applied Science Inc.). Hybridization signals were detected using the DIG Luminescent Detection Kit (Roche Applied Science Inc.).
Quantitative RT-PCR in cultured neurons. Cultured hippocampal and cortical
neurons from Slitrk2-ﬂoxed mice were infected with ΔCre or Cre lentivirus at
DIV4. Infected neurons were homogenized at DIV12 in TRIzol Reagent (Invitrogen), and total RNA was extracted according to the manufacturer’s protocol. cDNA
was prepared from total RNA using a cDNA synthesis kit (Takara Bio). qRT-PCR
was performed on a CFX96 Real-Time PCR system (Bio-Rad) with TB Green
reagents (Takara Bio) using a Slitrk2-speciﬁc probe (forward, 5′-GCAGAGCTTGCAGTATCTCTATT-3′; reverse, 5′-GGACCTCAGCAGGTTGTTATT-3′). A probe for Gapdh (forward, 5′-ACATGGTCTACATGTTCCAG-3′;
reverse, 5′-TCGCTCCTGGAAGATGGTGAT-3′) was used as an endogenous
control.
Structural modeling. The domain structures of human SLITRK2 (LRR1, aa C33D270; LRR2, aa P341-P579) were modeled with AlphaFold222,23. LRR1 and LRR2
domains of human SLITRK2 were presumed to be connected by a ﬂexible linker
based on previous negative-stain electron microscopy images of the full
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ectodomain of human SLITRK114. Protein stability of domain structures of human
SLITRK2 and variants was calculated using FoldX 5 suite49.
Nissl staining. Mice underwent intracardiac perfusion with PBS and then with 4%
paraformaldehyde. Fixed brain tissue was isolated, post-ﬁxed for 12 h at 4 °C, and
dehydrated in 30% sucrose for 6–8 d. Then, brain tissue was embedded in OCT
(Optimal Cutting Temperature) compound, frozen, cryo-sectioned at 20-µm
thicknesses using a cryostat (Leica CM5120). Slices were mounted on glass slides,
rinsed with PBS, and permeabilized with 0.1% Triton X-100 in PBS for 10 min.
Permeabilized samples were washed twice with PBS (5 min each), then incubated
for 20 min in 200 μl of NeuroTrace 500/525 Green Fluorescent Nissl Stain
(Molecular Probes), diluted 1:100 in PBS before use. Following three more washes
with PBS, the specimens were dried and mounted using Vectashield Mounting
Medium containing 4′,6-diamidino-2-phenylindole (DAPI; Vector Laboratories). A
slide scanner (Axio Scan.Z1; Carl Zeiss) was used to capture green ﬂuorescence.
Measurement of mouse ventricle volumes. Acute brain slices (50 µm thickness)
were obtained from 7-wk-old mice using a vibratome. Every sixth brain section
(300 µm between sections) was collected starting from bregma +0.86 mm and
continuing to the dorsal end at bregma −0.82 mm. Sections were immunostained
with anti-NeuN (clone A60; Millipore), and whole-brain slice images were obtained
using a slide scanner (Axio Scan.Z1; Carl Zeiss) with a ×20 objective lens. All image
settings were kept constant. Lateral ventricle areas were manually sketched and
calculated using MetaMorph software (Molecular Devices Corp.). Lateral ventricle
volumes were calculated as the sum of sectional areas of lateral ventricles times the
layer thickness.
Heterologous synapse-formation assays. Forty-eight hours after transfecting
with the indicated expression vectors, HEK293T cells were trypsinized, seeded onto
cultured hippocampal neurons at days in vitro (DIV)10, and cocultured for 48 h, as
indicated. Cocultured neurons were co-immunostained with antibodies against the
indicated proteins. Fluorescence images were acquired by confocal microscopy
(LSM780, Carl Zeiss), and results were quantiﬁed by measuring the ﬂuorescence
intensities of synaptic marker puncta in randomly selected transfected HEK293
cells (region of interest), normalized with respect to the area of each cell. Results
were quantiﬁed for both red and green channels using MetaMorph Software
(Molecular Devices Corp.; RRID: SCR_002368).
Primary neuronal culture, transfection, immunocytochemistry, and image
acquisition and analysis. Hippocampal and cortical mouse neuron cultures were
prepared from embryonic day 17 (E17) Slitrk2-ﬂoxed mouse embryos, as previously described50. In brief, neurons were seeded on 18-mm poly-D-lysine
(0.1 mg/ml)-coated coverslips and cultured in Neurobasal media (Gibco) containing penicillin-streptomycin and 0.5 mM GlutaMax (Thermo Fisher) supplemented with 2% B-27 (Thermo Fisher) and 0.5% FBS (Hyclone). Cultured
hippocampal neurons were infected with lentiviruses expressing Cre or inactive
Cre (ΔCre) recombinase at DIV5, and immunostained at DIV12 or DIV14. For
rescue experiments, hippocampal neurons were transfected at DIV8–9 with
SLITRK2 WT or the indicated point variants using a CalPhos Kit (Clontech) and
immunostained at DIV13–14; controls were transfected with EGFP. For
immunocytochemistry, cultured rat neurons were ﬁxed with 4% paraformaldehyde/4% sucrose in PBS for 30 min at 4 °C and permeabilized with 0.2% Triton
X-100 in PBS for 30 min at 4 °C. Neurons were then blocked by incubating with
3% horse serum/0.1% BSA in PBS for 15 min at room temperature, then stained
with the indicated primary and secondary antibodies for 70 min at room temperature. Z-stack images of randomly selected neurons were acquired using a
confocal microscope (LSM780; Carl Zeiss) with a ×63 objective lens. Obtained
Z-stack images were converted to maximal projections, and colocalized puncta
densities were analyzed in a blinded manner using MetaMorph software
(Molecular Devices Corp.).
Sholl analysis. Rat cultured hippocampal neurons were co-transfected with EGFP
and SLITRK2 WT or the indicated SLITRK2 variants for 5 d at DIV9. Transfected
neurons were stained with anti-EGFP and anti-HA antibodies, and costained
neurons were used for quantitative analysis. Dendritic branching was analyzed by
performing a Sholl analysis using the Scholl Analysis plugin installed in ImageJ
software (Fiji, RRID: SCR_002285), as previously described51. The number of
branches at increasing distances from the soma was quantiﬁed.
Stereotactic surgery. Mice were anesthetized with isoﬂurane (3–4%) and then
placed in a stereotaxic device. Viral solutions (titers ≥1 × 1011 viral genomes/ml)
were injected bilaterally at a rate of 0.2 µl/min with a NanoFil syringe and a
Nanoliter 2010 Injector (World Precision Instruments). The AP −2.5 mm, ML ±
1.7 mm, and DV −1.3 mm (from the dura) coordinates were used for hippocampal
CA1 regions. Mice were used ≥3 weeks after stereotactic surgeries.
Immunohistochemistry. Mice were transcardially perfused ﬁrst with PBS for
3 min and then with 4% paraformaldehyde in PBS for 5 min. After post-ﬁxation
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overnight, mouse brains were slowly sectioned at a thickness of 40 µm using a
vibratome (VT1200S; Leica). Brain sections were permeabilized by incubation with
0.2% Triton X-100 in PBS containing 10% horse serum and 0.2% BSA for 1 h at
room temperature. For immunostaining, sections were incubated overnight at 4 °C
with primary anti-VGLUT1 (1:500), anti-PSD-95 (1:500), or anti-VGAT (1:500)
antibodies diluted in the same blocking solution. After washing three times, sections were incubated with Cy3-conjugated secondary antibodies (Jackson ImmunoResearch) for 1 h at room temperature. Sections were then washed extensively
and mounted on glass slides with Vectashield Mounting Medium (Vector
Laboratories). Images were acquired by confocal microscopy (LSM700; Zeiss).
Synaptic puncta were quantiﬁed using MetaMorph software (Molecular Devices),
and their density and average area were measured.

Mouse behavioral tests. Male mice at the age of 6–10 weeks were used for all
behavioral tests. Tests were conducted in a sound-proof room under dim lighting
(<5 lux).
Open-ﬁeld test. Each mouse was placed into an open-ﬁeld apparatus
(40 × 40 × 40 cm) and allowed to freely explore the ﬁeld for 30 min. The total
distance traveled and time spent in the center area were recorded by a top-view
infrared camera and analyzed using EthoVision XT 10.5 (Noldus).
Three-chamber test. The testing apparatus consisted of a white acrylic box divided
into three chambers (20 × 40 × 22 cm each) with small openings on the dividing
walls. Wire cups were employed to enclose social conspeciﬁcs in the corners of both
side-chambers. Mouse was placed in the central chamber for a 10-min habituation.
Following habituation, an age-matched social conspeciﬁc was placed into the wire
cup on the left side-chamber, and the sociability of the subjects was assessed by
measuring subjects’ exploration times for the enclosed conspeciﬁc and the empty
cup during the second 10-min session. An exploration was counted when the
subjects directed their nose into the vicinity of the wire cups. In the last 10-min
session, a new social conspeciﬁc was placed into the empty wire cup on the right
side-chamber, and social recognition was assessed by measuring subjects’
exploration times for the familiar conspeciﬁc and the novel conspeciﬁc in a
wire cup
Elevated plus-maze test. The white acrylic maze with two open arms (30 × 5 × 0.5 cm)
and two closed arms (30 × 5 × 30 cm) was elevated 75 cm over the ﬂoor. Mice were
individually placed at the center of the elevated plus-maze and allowed to freely move
for 5 min. All behaviors were recorded by a top-view infrared camera, and the time
spent in each arm and the number of arm entries were analyzed using EthoVision XT
10.5 (Noldus).
Light and dark box test. The apparatus consists of a rooﬂess box divided into a
closed dark chamber and a brightly illuminated chamber. A small entrance allows
free travel between the two chambers. The light chamber was illuminated at 350
lux. The movement of mice was recorded by a top-view infrared camera and
EthoVision XT 10.5 (Noldus) was used for analysis of the time spent in each
chamber and the number of transitions
Y-maze test. Spatial working memory was evaluated on the basis of spontaneous
alternation behavior in a Y-maze consisting of three 40-cm-long arms at a 120°
angle from each other. Each mouse was placed at the center of the maze and
allowed to explore freely for 8 min. An entry was counted when the center point of
a mouse was within the arm. The movement of mice was recorded by a top-view
infrared camera and analyzed using EthoVision XT 10.5 (Noldus).
Novel object-recognition test. Object recognition test was performed in the openﬁeld box. On the ﬁrst day, mice were habituated to the maze for more than 10 min.
On the subsequent day, mice were allowed to explore two identical objects twice for
10 min. Exploration time for each object was measured. Twelve hours later, one of
two objects was replaced with a new distinct object and mice were returned to the
ﬁeld and allowed to explore for 10 min to test novel-object recognition. Exploration
time for each object was measured.
Barnes maze test. The Barnes maze test was conducted on a white circular platform,
95 cm in diameter, with 20 holes equally spaced around the perimeter. The hole
above the escape box represented the target. The location of the target was consistent for a given mouse but randomized across mice. The maze was rotated daily,
with the spatial location of the target unchanged with respect to the distal visual
room cues, to prevent a bias based on olfactory or proximal cues within the maze.
Three trials per day were conducted for 7 successive days. On day 10, the ﬁrst
probe trial was conducted without the escape box to conﬁrm that the spatial task
was acquired based on navigation by distal environment room cues. On day 17, the
second probe trial was conducted. During acquisition and probe trials, the following parameters were measured by a top-view infrared camera and analyzed
using EthoVision XT 10.5 (Noldus): velocity, error score, total distance, ﬁrst visit
time to escape box, and total latency.
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Grip strength test. A grip strength meter (BIOSEB) was used to measure forelimb
grip strength. A mouse was allowed to grasp the steel bar mounted on the force
gauge. The gauge was reset after stabilization, and the mouse’s tail was slowly
pulled back by an experimenter. Maximal grip force was automatically recorded as
newtons by the gauge. We performed 3 consecutive measurements per day for 3
consecutive days.
Gait test. The forepaws and hind paws of a mouse were coated with different
colored nontoxic acrylic paints. The mice were trained to run down the runway
(30-cm long and 5-cm wide) in a straight line before the test. The footprints were
traced on the white paper covering a runway. The footprints were analyzed for
overlap, each side of stride length, each side of stance length, and each side of sway
length. All parameters were analyzed by MetaMorph software (Molecular Devices
Corp.).

Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Data sets presented in this study are included in full wherever possible, including the
display of individual data points. All relevant data supporting the ﬁndings of this study
are available from the corresponding authors upon reasonable request. Biological
materials, including mutant mice and custom antibodies generated for this study, will be
shared upon request within the limits of respective material transfer agreements for as
long as they are available in the laboratory. Source data are provided with this paper.

Code availability
Electrophysiology
Cultured neuron electrophysiology. Hippocampal cultured neurons obtained from
Slitrk2-cKO mice were infected on DIV4 with lentiviruses encoding Cre‐EGFP or
ΔCre‐EGFP, followed by analysis at DIV13–16. Similarly, hippocampal cultured
neurons obtained from Nestin-Slitrk2 mice were analyzed at DIV13–16. Pipettes
were pulled from borosilicate glass (o.d. 1.5 mm, i.d. 0.86 mm; Sutter Instruments)
using a Model P‐97 pipette puller (Sutter Instruments). The resistance of patch
pipettes ﬁlled with internal solution varied between 3 and 6 MΩ. The internal
solution contained 145 mM CsCl, 5 mM NaCl, 10 mM HEPES, 10 mM EGTA,
0.3 mM Na‐GTP and 4 mM Mg‐ATP, with pH adjusted to 7.2–7.4 with CsOH and
an osmolarity of 290–295 mOsmol/l. The external solution consisted of 130 mM
NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM D‐
glucose, with pH adjusted to 7.2–7.4 with NaOH and an osmolarity of
300–305 mOsmol/l. The whole‐cell conﬁguration was obtained at room temperature using μM-TSC manipulators (SENSAPEX). Electrophysiological data were
acquired with a Multiclamp 700B ampliﬁer (Axon instrument) and pCLAMP
software, and were digitized using an Axon DigiData 1550B data acquisition board
(Axon Instruments). mEPSCs were recorded at a holding potential of −70 mV.
Synaptic currents were analyzed ofﬂine using Clampﬁt 10.8 software (Molecular
Devices). For mEPSC recordings, the external solution contained 1 μM TTX and
50 μM picrotoxin to block GABAA receptor and Na+ currents, respectively. For
mIPSC recordings, the external solution contained 1 µM TTX, 10 µM CNQX, and
50 µM D-AP5 to block Na+ currents, AMPA receptors, and NMDA receptors,
respectively.
Hippocampal CA1 pyramidal neuron electrophysiology. Whole-cell voltage-clamp
recordings were obtained from acute brain slices. Brain slices were transferred to a
recording chamber and perfused with a bath solution of aerated (O2 95%/CO2 5%
mixed gas) artiﬁcial cerebrospinal ﬂuid (aCSF) consisting of 124 mM NaCl, 3.3 mM
KCl, 1.3 mM NaH2PO4, 26 mM NaHCO3, 11 mM D-glucose, 2.5 mM CaCl2, and
1.5 mM MgCl2 at 28–30 °C. For measuring postsynaptic currents, patch pipettes
(open pipette resistance, 3–5 MΩ) were ﬁlled with an internal solution consisting of
145 mM CsCl, 5 mM NaCl, 10 mM HEPES, 10 mM EGTA, 4 mM Mg–ATP, and
0.3 mM Na–GTP. Whole-cell recordings of mEPSCs were performed on CA1
pyramidal neurons, voltage clamped at −70 mV, and currents were pharmacologically isolated by bath applications of 50 µM picrotoxin (Tocris), 1 µM tetrodotoxin (Tocris). Electrophysiological data were acquired using pCLAMP software
and a MultiClamp 700B (Axon Instruments) and were digitized using an Axon
DigiData 1550B data acquisition board (Axon Instruments). Data were sampled at
10 kHz and ﬁltered at 4 kHz. Data were discarded if the series resistance was
>30 MU, or the series resistance differed by more than 20%.

Data analyses. Data analysis and statistical tests were performed using GraphPad
Prism8.0 software (RRID: SCR_002798). Heterologous synapse-formation assays
and surface-binding assays were quantiﬁed by randomly selecting transfected
HEK293T cells as the region of interest. The ﬂuorescence intensities of synaptic
marker puncta or Fc-fusion proteins were normalized to transfected protein signal
intensities using MetaMorph software (Molecular Devices Corp.). All data are
expressed as means ± standard error of the mean (SEM) unless stated otherwise,
and signiﬁcance is indicated with an asterisk. All experiments were performed
using at least three independent mice, cultures, and/or cohorts of grouped mice,
and the normality of data distributions was evaluated using the Shapiro–Wilk test.
Data were compared using Student’s t-test or one-way analysis of variance
(ANOVA) using a non-parametric Kruskal–Wallis test, followed by Dunn’s multiple comparison test for post hoc group comparisons, t-test, Mann–Whitney U
test, or Fisher’s least signiﬁcance difference; ‘n’ values used are indicated in the
ﬁgure legends, and numbers shown indicate replicates. Tests used to determine
statistical signiﬁcance are stated in the text and legends of ﬁgures depicting the
results of the respective experiments. A p-value <0.05 was considered statistically
signiﬁcant, and individual p-values are indicated in the respective ﬁgure legend. All
experiments were performed and analyzed in a blind manner by the experimenter.

All relevant code supporting the ﬁndings of this study is available from the
corresponding authors upon request.
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